Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07826767) titled 'Open-label Gene Therapy Study in p47-CGD' on Sept. 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Somagenetix AG
Condition:
Chronic Granulomatous Disease (CGD)
Intervention:
Biological: SGX-001
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 18, 2026
Target Sample Size: 5
Countries of Recruitment:
Germany
Spain
Switzerland
Germany
Spain
Switzerland
To know more, visit https://clinicaltrials.gov/study/NCT07826767
Published by HT Dig...